JP2023507981A - 生物医薬組成物および関連の方法 - Google Patents

生物医薬組成物および関連の方法 Download PDF

Info

Publication number
JP2023507981A
JP2023507981A JP2022537240A JP2022537240A JP2023507981A JP 2023507981 A JP2023507981 A JP 2023507981A JP 2022537240 A JP2022537240 A JP 2022537240A JP 2022537240 A JP2022537240 A JP 2022537240A JP 2023507981 A JP2023507981 A JP 2023507981A
Authority
JP
Japan
Prior art keywords
seq
composition
less
heavy chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507981A5 (https=
Inventor
ケリー、ニーロン
ミンシュアン、チャン
Original Assignee
テサロ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テサロ， インコーポレイテッド filed Critical テサロ， インコーポレイテッド
Publication of JP2023507981A publication Critical patent/JP2023507981A/ja
Publication of JP2023507981A5 publication Critical patent/JP2023507981A5/ja
Priority to JP2025185522A priority Critical patent/JP2026027328A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022537240A 2019-12-18 2020-12-10 生物医薬組成物および関連の方法 Pending JP2023507981A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025185522A JP2026027328A (ja) 2019-12-18 2025-11-04 生物医薬組成物および関連の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949696P 2019-12-18 2019-12-18
US62/949,696 2019-12-18
US201962950595P 2019-12-19 2019-12-19
US62/950,595 2019-12-19
PCT/US2020/064241 WO2021126657A1 (en) 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025185522A Division JP2026027328A (ja) 2019-12-18 2025-11-04 生物医薬組成物および関連の方法

Publications (2)

Publication Number Publication Date
JP2023507981A true JP2023507981A (ja) 2023-02-28
JP2023507981A5 JP2023507981A5 (https=) 2023-12-19

Family

ID=74125707

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537240A Pending JP2023507981A (ja) 2019-12-18 2020-12-10 生物医薬組成物および関連の方法
JP2025185522A Pending JP2026027328A (ja) 2019-12-18 2025-11-04 生物医薬組成物および関連の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025185522A Pending JP2026027328A (ja) 2019-12-18 2025-11-04 生物医薬組成物および関連の方法

Country Status (11)

Country Link
US (1) US20230059341A1 (https=)
EP (1) EP4077388A1 (https=)
JP (2) JP2023507981A (https=)
KR (1) KR20220129548A (https=)
CN (1) CN115298218A (https=)
AU (2) AU2020407007A1 (https=)
BR (1) BR112022014694A2 (https=)
CA (1) CA3164600A1 (https=)
IL (1) IL293753A (https=)
MX (1) MX2022007464A (https=)
WO (1) WO2021126657A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4076385T1 (sl) * 2019-12-20 2026-04-30 Formycon Ag Formulacije protiteles anti-pd1
WO2024118587A1 (en) * 2022-11-30 2024-06-06 Tesaro, Inc. Methods of treating cancer with anti-pd-1-antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129559A1 (en) * 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-pd-1 antibodies
JP2018526369A (ja) * 2015-08-24 2018-09-13 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ バイオ医薬組成物
WO2018204368A1 (en) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP2019533458A (ja) * 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死１（ｐｄ−１）に対する抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
CN106999591B (zh) * 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体制剂及其在医药上的应用
LT3386541T (lt) * 2015-12-07 2020-10-26 Merck Patent Gmbh Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526369A (ja) * 2015-08-24 2018-09-13 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ バイオ医薬組成物
JP2019533458A (ja) * 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死１（ｐｄ−１）に対する抗体
WO2018129559A1 (en) * 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-pd-1 antibodies
WO2018204368A1 (en) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MABS, vol. vol.6, issue 5, JPN6024047196, 2014, pages 1145 - 1154, ISSN: 0005779364 *
YTHER, R., ET AL.: "Quality Issues Arising from Post-translational Modification of Recombinant Antibodies", CELL ENGINEERING, VOL.7; ANTIBODY EXPRESSION AND PRODUCTION, JPN6024047197, 2011, pages 293 - 303, ISSN: 0005779363 *

Also Published As

Publication number Publication date
AU2025203823A1 (en) 2025-06-19
IL293753A (en) 2022-08-01
CN115298218A (zh) 2022-11-04
EP4077388A1 (en) 2022-10-26
AU2020407007A1 (en) 2022-06-23
CA3164600A1 (en) 2021-06-24
MX2022007464A (es) 2022-06-27
WO2021126657A1 (en) 2021-06-24
JP2026027328A (ja) 2026-02-18
US20230059341A1 (en) 2023-02-23
BR112022014694A2 (pt) 2022-09-06
KR20220129548A (ko) 2022-09-23

Similar Documents

Publication Publication Date Title
US20240158495A1 (en) Antibody Agents Directed Against Lymphocyte Activation Gene-3 (LAG-3) and Uses Thereof
IL293244B2 (en) Anti-icos agonist antibodies and uses thereof
JP7593939B2 (ja) 抗ｍｅｒｔｋ抗体及びその使用方法
JP2020504141A (ja) 抗ｐｄ−１抗体を用いてがんを処置する方法
US20150259419A1 (en) Anti-MCAM Antibodies and Associated Methods of Use
CN110546163A (zh) 抗-tigit抗原结合蛋白及其使用方法
JP2026027328A (ja) 生物医薬組成物および関連の方法
WO2017149513A1 (en) Anti-mcam antibodies and associated methods of use
WO2017208210A1 (en) Anti-mcam antibodies and associated methods of use
KR20250153216A (ko) Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
TW202233671A (zh) Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
TW202330027A (zh) 抗ｃｄ－４７抗體製劑
WO2023186113A9 (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
US20250340643A1 (en) Anti-CTLA Antibody Compositions and Related Methods
BR122024025522A2 (pt) Composições biofarmacêuticas, formulação, dispositivo de injeção, meio de cultura celular e eluato que compreendem as ditas composições e usos terapêuticos das mesmas
HK40083648A (zh) 生物藥物組合物和相關方法
JP2022544850A (ja) 抗ｐｄ１抗体プロルゴリマブの水性医薬組成物およびその使用
CN118946583A (zh) 用t细胞接合分子治疗前列腺癌的联合治疗方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251104